RXR activators molecular signalling: involvement of a PPARα‐dependent pathway in the liver and kidney, evidence for an alternative pathway in the heart
- 1 March 2003
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 138 (5) , 845-854
- https://doi.org/10.1038/sj.bjp.0705113
Abstract
(1) In this study we compared the molecular signalling elicited by rexinoids, selective retinoid X receptor (RXR)-activators, in several organs (i.e. liver, kidney, heart) and in hepatocytes of various species. (2) RXR plays the pivotal role of a hetero-dimerization partner for the members of the class II subset of nuclear receptors which regulate the transcription of numerous target genes, following chemical activation. Several of these selective activators are currently used to treat hyperlipidaemia (fibrates), type II diabetes (glitazones), or skin disorders (retinoic acid). Although these therapeutic pathways are not fully elucidated, receptor activation is considered a pre-requisite for efficacy. Therefore RXR, which accepts numerous dimeric partners, is considered a worthwhile pharmacological target. (3) We analysed a number of biochemical and molecular responses to rexinoids which were given orally to mice. Our results showed a prominent involvement of the peroxisome proliferator-activated receptor (PPARalpha) as a majority of the observed hepatic and renal regulations were abolished in PPARalpha-knockout animals. Therefore we documented the species-specificity of these rexinoid actions which were reproduced in rat primary hepatocyte cultures but not in cultures of rabbit or human origin. Conversely, we established that the regulation of the pyruvate dehydrogenase kinase (PDK4) gene in the heart, by rexinoids, is independent of PPARalpha expression. (4) Our results support the obligatory expression of the active, although quiescent, PPARalpha to sustain a subset of relevant regulations attributable to rexinoids in the liver and kidney. Their cardiac molecular signalling unveiled an alternate transduction pathway and therefore opens new prospects in the therapeutic potential of rexinoids.Keywords
This publication has 52 references indexed in Scilit:
- Up-regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) protein expression in oxidative skeletal muscle does not require the obligatory participation of peroxisome-proliferator-activated receptor α (PPARα)Biochemical Journal, 2002
- Functional Evidence for Retinoid X Receptor (RXR) as a Nonsilent Partner in the Thyroid Hormone Receptor/RXR HeterodimerMolecular and Cellular Biology, 2002
- Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation Is Mediated by Peroxisome Proliferator-Activated Receptor αBiochemical and Biophysical Research Communications, 2001
- Hepatocyte-Specific Mutation Establishes Retinoid X Receptor α as a Heterodimeric Integrator of Multiple Physiological Processes in the LiverMolecular and Cellular Biology, 2000
- Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARαToxicology Letters, 2000
- Peroxisome Proliferator-activated Receptor α-Isoform Deficiency Leads to Progressive Dyslipidemia with Sexually Dimorphic Obesity and SteatosisJournal of Biological Chemistry, 1998
- Retinoid-Induced Hypertriglyceridemia in Rats Is Mediated by Retinoic Acid ReceptorsFundamental and Applied Toxicology, 1996
- The RXR heterodimers and orphan receptorsPublished by Elsevier ,1995
- Section Review: Retinoids: Biological Function and Use in the Treatment of Dermatological Diseases: Pulmonary-Allergy, Dermatological, Gastrointestinal & ArthritisExpert Opinion on Investigational Drugs, 1995
- Peroxisome proliferation due to di(2-ethylhexyl) phthalate (DEHP): species differences and possible mechanisms.Environmental Health Perspectives, 1986